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Available online 22 November 2018Age-relatedmacular degeneration (AMD) is the leading cause of blindness in the elderly in developed countries.
Neovascular AMD (nAMD) accounts for 90% of AMD-related vision loss. Although intravitreal injection of VEGF
inhibitors can improve vision in nAMD, approximately 1/3 of patients do not beneﬁt from the therapy due to
macular ﬁbrosis. Themolecularmechanism underlying the transition of the neovascular lesion to a ﬁbrovascular
phenotype remains unknown. Herewe discussed the clinical features and risk factors of macular ﬁbrosis second-
ary to nAMD. Myoﬁbroblasts are key cells in ﬁbrosis development. However, ﬁbroblasts do not exist in the mac-
ula. Potential sources of myoﬁbroblast precursors, the molecular cues in the macular microenvironment that
recruit them and the pathways that control their differentiation and activation in macular ﬁbrosis were also
discussed. Furthermore,wehighlighted the challenges inmacular ﬁbrosis research and the urgent need for better
animal models for mechanistic and therapeutic studies.titute for
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Age related macular degeneration (AMD) is the progressive degen-
eration of the central part of the neuronal retina, the macula, in people
older than 55 years of age, and is the leading cause of blindness in the
elderly in industrialized countries [1]. Ageing, urbanization, obesity
and cigarette smoke are risk factors for AMD [1]. Due to the growing
ageing population and increased life expectancy, it has been projected
that 288 million people will be affected by AMD by 2040 [2,3]. The
early stage of AMD is characterized by large drusen and disturbance
of retinal pigment epithelial (RPE) cells. The disease can advance
into two late stages, “dry” and “wet”. Dry AMD refers to the geo-
graphic atrophy of the macula (Fig. 1A, B); whereas wet AMD is the
growth of abnormal blood vessels into the macula (Fig. 1C, D), also
known as neovascular AMD (nAMD). nAMD is treated by intravitreal
injection of vascular endothelial growth factor inhibitors (e.g., anti-
VEGF). Although the treatment can prevent the decrease or even im-
prove vision acuity, it is burdensome, costly and invasive. Importantly,
approximately one-third of patients do not beneﬁt from the therapy
due to the development of macular ﬁbrosis or atrophy. The pathogen-
esis of macular ﬁbrosis in nAMD is poorly deﬁned, and currently there
is no therapy for it. This review discusses the clinical manifestations
and the underlying mechanisms of macular ﬁbrosis secondary to
nAMD with a strong focus on the potential source of myoﬁbroblastFig. 1. Clinical features of late stages of AMD. (A, B) “dry”AMD (Geography atrophy), sharply cir
were seen in color photography (A). Loss of RPE (red arrows) and morphologic alteration o
(C) Subretinal exudation and hemorrhage (black asterisk) were shown on the fundus photogr
ﬁber layer; GL: ganglion layer; ONL: outer nuclear layer; OLM: outer limiting membrane; EZ: eprecursors and the pathways involved in their recruitment and
activation.
2. Clinical features of macular ﬁbrosis in nAMD
2.1. Neovascular AMD
The growth of new blood vessels into the macula is the hallmark of
nAMD. The new vessels cause leakage and hemorrhage beneath the
RPE or photoreceptors resulting in severe visual loss. nAMD is classiﬁed
into three subtypes according to the origin of diseased vessels, choroidal
neovascularization (CNV) (Fig. 2A–D), retinal angiomatous proliferation
(RAP) (Fig. 2E, F), and polypoidal choroidal vasculopathy (PCV) (Fig. 2G,
H). CNV originates from choroidal blood vessels, which can be further
classiﬁed into occult (CNV spreads beneath RPE cells, Fig. 2A, B) and
classic (CNV breaks through RPE layer and grows in subretinal space,
Fig. 2C, D) subtypes. RAP is the proliferation of retinal blood vessels
that progress posteriorly into the subretinal space causing retinal-
choroidal anastomosis (Fig. 2E, F) [4]. RAP accounts for 15% to 20% of
all nAMD cases in Caucasian population [4]. PCV is the polypoidal dilata-
tions of an abnormal branching choroidal vascular network (BVN)
(Fig. 2G, H), which can penetrate Bruch's membrane and spread into
subretinal space of the macula [5]. PCV is more prevalent than RAP in
Asian populations [5].cumscribed areas of RPE atrophy (black asterisks) associated scattered pre-existing drusen
f the outer retina (yellow asterisks) on SD-OCT B-scan (B). (C, D) “wet” AMD (nAMD).
aph. (D) Fibrovascular lesion penetrates the RPE on SD-OCT (yellow asterisk). NL: Nerve
llipsoid zone; RPE: retinal pigment epithelia; Ch: Choroid.
Fig. 2. Clinical features of different types of nAMD. (A, B) Occult CNV (type 1 CNV). Whitish hard exudation scattered around the swollen foveola (A). SD-OCT showed dome-shape
elevation of intact RPE (B, red arrow) with intermediate hype- reﬂective mass (yellow asterisk). Bruch's membrane was intact (white arrow). OLM: outer limiting membrane; EZ:
ellipsoid zone; RPE: retinal pigment epithelia. (C, D) Classic CNV (type 2 CNV). Subretinal exudation (C, black asterisk) with ﬁbrovascular lesion (D, yellow asterisk) penetrates the RPE
(D, red arrow). The adjacent RPE contain subretinal hyper-reﬂective materials (SHRM, arrowheads). (E, F) Retinal angiomatous proliferation (RAP), proliferating vessels within and
below the retina. Retinal vessels (E. black arrows) connecting to the disciform scar. SD-OCT shows retinal vessel (F, blue arrow) insets into the sub-retinal hyper-reﬂective lesion (F,
white arrows). (G, H) Polypoidal choroidal vasculopathy (PCV). Orange lesion (G, black asterisk) and subretinal hemorrhage were seen on color photograph. SD-OCT shows the
thumb-like RPE detachment (H, green arrow) well correspond to polypoidal lesions, and the double layer sign (H, intermediate hype-reﬂective membrane located between RPE and
Bruch's membrane (white arrow)), which corresponds to the branched vascular network.
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Macularﬁbrosis is the end stageof thenatural historyof nAMD[6,7]. It
was originally described as disciform lesions by Pagenstecher in 1875,
and was later found to be ﬁbrotic scarring in histopathological examina-
tions [8]. Macular ﬁbrosis damages the RPE and photoreceptors resultingin irreversible visual impairment even with anti-VEGF agent treatment
[9,10]. The incidence of macular ﬁbrosis in nAMDwas reported to range
from 39% [11] to 100% [12] 10–15 years ago; and was decreased to
20·37–61·4% after the introduction of anti-VEGF therapy [9,13,14].
Clinically, macular ﬁbrosis is deﬁned as a well-demarcated, elevated
mound of whitish or yellowish material within or under the retina that
286 K. Little et al. / EBioMedicine 38 (2018) 283–291is not dehomoglobinized blood or hard exudation on fundus
examination [13–15] (Fig. 3A). Fluorescein angiography (FA) usually
demonstrates early hypoﬂuorescent plaque masking the underneath
(Fig. 3C) followed by non-leakage hyperﬂuorescein in the late stage
(Fig. 3D). On spectral-domain optical coherence tomography
(SD-OCT), ﬁbrosis appears as a compact, subretinal hyper-reﬂective le-
sion,with aberrant RPE and ellipsoid zone (Fig. 3B, E) [15]. Subretinal ﬁ-
brosis was classiﬁed into three stages using OCT and color fundus
tomography [15]. Stage I: Minimal subretinal ﬁbrosis - with a distinct
pale patch lesion in fundus photograph and a thin continuous, highly
reﬂective band on OCT between a grossly intact outer neurosensory ret-
ina and Bruch's membrane, with or without subretinal ﬂuid. Stage II:
Prominent subretinal ﬁbrosis - with a thick, continuous, highly reﬂec-
tive subretinal mass and diffuse thickening of the neurosensory fovea.
Stage III: Hyper-reﬂective subretinal ﬁbrosis - with atrophy of the over-
lying neurosensory retina [15]. On optical coherence tomography angi-
ography (OCTA), abnormal vascular network and collateral
architectural changes in the outer retina and the choriocapillaris layerFig. 3. Clinical features of macular ﬁbrosis. (A) Well-circumscribed white ﬁbrous tissue was see
asterisk) with overlying aberrant outer retinal components (red arrows) and cystic lesions (wh
(C, 1 min 27 s) and hyper-ﬂuorescent at late stage (D, 11 min 49 s) (red asterisks). (E) SD-OCTw
blood ﬂow signals inside (red color dots). The overlying neurosensory retina was thinning and
dotted circle).are often evident, suggesting that the lesions are vascularized ﬁbrotic
membranes (Fig. 3E, F) [14].
2.3. Risk factors of retinal ﬁbrosis in nAMD
AMD is related to several environmental and genetic risk factors.
Age, smoking and diet are most consistently associated environmental
risk factors of AMD [16]. Genetic studies have shown that the comple-
ment factor H (CFH) on chromosome 1 and the age-related
maculopathy susceptibility 2/HtrA serine peptidase (ARMS2/HTRA1)
genes on chromosome 10 have AMD susceptibility loci [17,18].
However, the environmental and genetic factors related to macular ﬁ-
brosis in AMD have not been identiﬁed. Singh et al. reported that
lower plasma levels of 25-hydroxyvitamin D is associated with
subretinal ﬁbrosis in nAMD [19]. The CFH Y402H CC genotype in
nAMD patients is known to be related to poor response to anti-VEGF
therapy, and patients with ﬁbrosis are often poor responders [20]. This
suggests that the CFH Y402H CC genotype may be a genetic risk factorn (blue asterisk). (B) SD-OCT shows well-deﬁned hyper-reﬂective sub-retinal tissue (blue
ite asterisk). (C and D) Fluorescein angiography shows hypo-ﬂuorescent at the early stage
ith blood ﬂow overlay shows hyper-reﬂective subretinal ﬁbrosis (green dotted line) with
atrophic. (F) en Face OCT-A shows blood vessels within the ﬁbrous tissue (within the red
287K. Little et al. / EBioMedicine 38 (2018) 283–291for macular ﬁbrosis, although direct evidence supporting the claim is
lacking.
Amongdifferent types of nAMD, patientswith RAP aremore likely to
develop macular ﬁbrosis [21] than those with PCV [22]. Furthermore,
classic CNV, poorer visual acuity at ﬁrst presentation, a longer interval
between diagnosis and treatment [13], refractory intraretinal cysts
[23] and macular hemorrhage [24] are known risk factors of retinal ﬁ-
brosis. SD-OCT investigations have shown that the presence of
subretinal hyper-reﬂective material (SHRM, Fig. 2D) in RPE is related
tomacularﬁbrosis and poor vision prognosis [25]. In particular, the cen-
tral location, a well-deﬁned border and the thickness of SHRM can pre-
dict the likelihood of subretinal ﬁbrosis [26]. The clinical observations
suggest that damage to the neuronal retina and RPE put the macula at
risk of developing ﬁbrosis in nAMD.
3. Pathophysiology of macular ﬁbrosis
Fibrosis is a pathological state of excess deposition of extracellular
matrix (ECM) proteins in tissue repair. Wound healing occurs when in-
jury to the tissue causes the recruitment and activation of inﬂammatory
cells and ﬁbroblasts. Activated ﬁbroblasts (myoﬁbroblasts) proliferate
and deposit ECM proteins such as collagens, ﬁbronectin, laminin and
glycosaminoglycans. ECM spreads to cover and regenerate the damaged
tissue. When repeated injuries occur or during chronic inﬂammation,
this process becomes uncontrolled resulting in excessive ﬁbrotic
scarring. Macular ﬁbrosis in nAMD has unique pathological features.
First, it originates from a pre-existing neovascular membrane.
Therefore, it is a conversion of the diseased vessels into ﬁbrous tissues.
Second, the ﬁbrous tissue often has a vascular network (Fig. 3) i.e., a ﬁ-
brovascular membrane [14].
The origin ofmyoﬁbroblasts and the underlyingmechanisms of ECM
deposition in macular ﬁbrosis remain poorly deﬁned. It has been sug-
gested that the macular scar may originate from retinal glial cells
(e.g., Müller cells, microglia and astroglia) [27]. Histological studies in
surgically removed CNV membranes (CNVMs) from nAMD patients
have reportedmultiple cell types, including endothelial cells, RPE, mac-
rophages and ﬁbroblast-like cells [28]. Importantly, α-smooth muscle
actin (α-SMA) positive cells, a characteristic marker of myoﬁbroblasts
have also been detected in CNVMs [29]. The results suggest that multi-
ple cells may contribute to macular ﬁbrosis.
4. Molecular mechanism of macular ﬁbrosis in nAMD
The function of themyoﬁbroblast is to synthesise andmaintain ECM
proteins. Since the retina and newblood vessels in nAMDdo not contain
ﬁbroblasts, myoﬁbroblasts inmacular ﬁbrosis must have been recruited
or differentiated from other cells.
4.1. The potential sources of myoﬁbroblast precursors in macular ﬁbrosis
4.1.1. Glial cells
Müller glia and astrocytes provide framework support to retinal
neurons and vasculatures. Under disease conditions, such as diabetic
retinopathy and AMD, reactive Müller glia and astrocytes produce a va-
riety of ECM and participate in retinal repair and remodeling [27]. Glial
ﬁbrillary acidic protein (GFAP) positive cells have been detected in an
experimental model of subretinal ﬁbrosis [30]. Under in vitro culture
conditions, Müller cells lose the expression of glutamine synthetase
and GFAP but gain the expression of αSMA suggesting that they have
the potential to transdifferentiate into myoﬁbroblasts [31]. Whether
Müller cells can transdifferentiate into myoﬁbroblasts in nAMD war-
rants further investigation.
4.1.2. RPE cells
RPE cells are known to contribute to retinal ﬁbrosis, including mac-
ular ﬁbrosis [32,33] through Epithelial-Mesenchymal Transition (EMT).The EMT is well-known as a contributing process in kidney, liver and
lung ﬁbrosis [34–36]. Clinical studies have observed higher incidence
of ﬁbrosis in classic CNV (compared with occult CNV) [13], in which
the neovascular membrane penetrates the Bruch's membrane-RPE
complex into the subretinal space. Damaged RPE cells may become
myoﬁbroblasts through EMT and contribute tomacular ﬁbrosis. Various
in vitro studies have shown that RPE cells can undergo EMT under ex-
perimental conditions [32,37]. Senescent cells can secrete a number of
matrixmetalloproteinases (MMPs) that are important for limitingﬁbro-
sis [38]. However, chronic presence of MMPs by senescent cells can
damage tissue structure and function by inducing EMT [38]. Senescent
RPE cells in nAMD may induce EMT by secreting MMPs.
4.1.3. Endothelial cells
Endothelial to mesenchymal transition (EndoMT) is known to con-
tribute to organ ﬁbrosis [39]. Endothelial cells of the neovascular mem-
brane in nAMD are highly active, and they may transdifferentiate into
myoﬁbroblasts through EndoMT contributing to macular ﬁbrosis. An
EndoMT transcription factor, SNAI1 has been shown to critically con-
tribute to the development of CNV [40]. The overall incidence of macu-
lar ﬁbrosis has been reduced since the approval of intravitreal injection
of VEGF inhibitors as a standard of care for nAMD. The results suggest
that endothelial cells may contribute to macular ﬁbrosis in nAMD.
4.1.4. Macrophages
Macrophages play an important role in tissue repair and wound
healing [41]. A previous study has shown that 20% of the cells in
experimental CNVweremacrophages, and themajority (70%) ofmacro-
phages originated from thebonemarrow [42]. During the early stages of
inﬂammation, pro-inﬂammatory M1-macrophages produce cytokines
to eliminate pathogens. After the inﬂammatory response subsides,
M2-macrophages facilitate tissue repair by stimulating cellular prolifer-
ation and differentiation. Both M1 and M2macrophages can participat-
ing in tissue ﬁbrosis by secreting transforming growth factor – β (TGFβ)
[41]. Later, macrophages may switch to a pro-resolving phenotype that
suppresses the tissue-damaging inﬂammation and dissolves excessive
ECM proteins [41].When the pathogenic stimuli persist for a prolonged
period, such as in AMD, the inﬂammatory and repair process may be
dysregulated or maladapted leading to destructive ﬁbrosis.
Macrophages can directly transdifferentiate to myoﬁbroblasts, and
this phenomenon is known to contribute to renal ﬁbrosis [43]. Using
lineage tracing studies, it was reported that the majority of macro-
phages undergoing MMT were CD206+ M2 macrophages [44]. Macro-
phages are capable of producing ECM proteins. Under in vitro culture
conditions, TGFβ can induce macrophage expression of αSMA (Fig. 4),
collagen 1 and ﬁbronectin, suggesting that they can undergo Macro-
phage toMyoﬁbroblast Transition (MMT).
4.1.5. Circulating ﬁbrocytes
Circulating ﬁbrocytes are a distinct population of blood-borne inac-
tive mesenchymal cells that can enter tissue and become ﬁbroblasts.
They express the hematopoietic marker CD45, the progenitor marker
CD34, and collagen. During tissue injury and inﬂammation, the levels
of circulating ﬁbrocytes are increased [45] and they may participate in
wound healing and ﬁbrotic tissue repair. Fibrocytes have been detected
in CNVMs [28] and they may be an important source of myoﬁbroblasts
in macular ﬁbrosis.
4.1.6. Choroidal stromal cells
Choroidal stroma contains melanocytes, macrophages, ﬁbroblasts,
lymphocytes and mast cells, as well as collagen and elastic ﬁbres. Vari-
ous choroidal stromal cells have been detected in the experimental
model CNV and ﬁbrosis [28]. A recent study in a mouse model of CNV/
ﬁbrosis has shown that choroidal pericytes can inﬁltrate the CNV and
differentiate into collagen 1-expressing cells [46]. The choroidal stromal
cells may be a potential source of myoﬁbroblast precursors.
Fig. 4.Macrophage-to-myoﬁbroblast transition. A proportion of murine bone marrow derived macrophages treated with recombinant TGF-β for (96 h). The cells were stained for F4/80
(green) and αSMA (red) and imaged by confocal microscopy. (A) Two macrophages express αSMA in control macrophages. (B) Many more cells express αSMA in TGFβ treated
macrophages.
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precursors
Clinical studies have shown nAMD eyes with persistent retinal and
RPE disruption are more likely to develop ﬁbrosis. This highlights the
importance of retinal microenvironment in disease pathogenesis. A
low-grade chronic inﬂammation is known to play an important role in
AMD [47]. During inﬂammation, retinal cells (e.g., RPE and microglia)
and inﬁltrating immune cells produce various cytokines and
chemokines that may recruit myoﬁbroblast precursors to the macula.
For example, RPE, microglia and macrophages can all produce CCL2, a
chemokine that plays an important role in the recruitment of CCR2+
macrophages [48] and ﬁbrocytes [49]. CCR2+ macrophages critically
contribute to the development of retinal neovascular membrane in
laser-induced CNV [50] and chronic autoimmune uveoretinitis [51].
The cyclooxygenase-2 (COX-2) is also implicated in the recruitment of
macrophages in the laser-induced CNV and selective inhibition of
COX-2 suppresses CNV and subretinal ﬁbrosis [52].
Fibrocytes express the chemokine receptors CCR2, CCR7 and CXCR4
that control their trafﬁcking to sites of injury [53]. Different chemokine/
chemokine receptor pathways are involved in ﬁbrocyte trafﬁcking
under different pathological conditions. For example, in asthma, the
CXCR4/CXCL12 axis critically controls ﬁbrocyte inﬁltration during
acute inﬂammation, whereas, the CCR7/CCL19 axis plays an important
role in ﬁbrocyte trafﬁcking in chronic obstructive asthma [54]. In addi-
tion, the platelet-derived growth factor (PDGF) [55] and thymic stromal
lymphopoietin [56] are also known to play a role in ﬁbrocyte trafﬁcking.
The cells responsible for the recruitment of myoﬁbroblast precursors in
nAMD may include inﬁltrating macrophages, active endothelial cells
and RPE. However, the underlying molecular pathways remain elusive.4.3. Molecular pathways involved in the differentiation and activation of
myoﬁbroblasts
4.3.1. Transforming growth factor-β (TGFβ)
TGFβ is the ‘master regulator’ of ﬁbrosis. The TGFβ family consists of
around 30 members, and many of them signal via the SMAD signaling
pathway. TGFβ has been implicated in the EMT [32,34] and MMT [44].
Previous studies have shown that the TGFβ-induced EMT in RPE cells in-
volves the mitogen-activated protein kinases (ERK, p38 and JNK),
SMAD2 and AKT pathways [57], which can be attenuated by activating
the retinoic acid receptor-γ (RARγ) pathway [57]. EMT may also be in-
duced by non-SMAD signaling pathways such as the wnt/β-catenin
pathway [58]. ReactiveOxygen Species (ROS) is known to activateﬁbro-
blasts and increase collagen deposition in ﬁbrosis through converting
the latent form of TGFβ into its active form [59]. Oxidative stress is a
major contributor of AMD, and ROS production by RPE or inﬂammatory
cells may participate in macular ﬁbrosis through activating TGFβ.4.3.2. Platelet-derived growth factor (PDGF)
PDGF is a potent mitogen for mesenchymal cells such as
myoﬁbroblasts [60]. It also critically controls their migration and prolif-
eration [60] and plays an important role in tissue repair, remodeling and
organ ﬁbrosis [60]. PDGF is critically involved in the pathogenesis of
nAMD. A phase-2 clinical trial in nAMD using a dual antagonism of
PDGF (Fovista) and VEGF (Ranibizumab) has observed signiﬁcant bene-
ﬁts, including reduced macular ﬁbrosis, compared with Ranibizumab
monotherapy [61]. However, a follow-up phase-3 study
(NCT01940900) did not conﬁrm the improvement in visual acuity. In-
terestingly, a recent in vitro study has shown that a combined VEGF/
PDGF inhibition induced a pro-ﬁbrotic phenotype in human pericytes
[62]. Further mechanistic studies may help to understand the role
PDGF in retinal ﬁbrosis.4.3.3. Connective tissue growth factor (CTGF)
CTGF is an extracellular matrix-associated heparin-binding protein
produced by many tissue cells including vascular endothelial cells
[63]. CTGF is critically involved in angiogenesis, tissue repair, and ﬁbro-
sis through stimulating activation and proliferation of ﬁbroblasts [64].
The role of CTGF in choroidal neovascularization [65] and retinal ﬁbrosis
[66] has been recognized for over a decade. A phase 1/2 trial with RXI-
109, a self-delivering CTGF-RNAi for retinal ﬁbrosis in nAMD has
shown that the compound iswell-toleratedwhen injected intravitreally
(NCT02599064) although the therapeutic potential remains to be
evaluated.4.3.4. Epidermal growth factor (EGF)
EGF is a small polypeptide of 53 amino acid residues produced by
many cells and is one of the best characterized epithelial cell mitogens
[67]. EGF binds to its receptor EGFR resulting in cellular proliferation,
differentiation, and survival [67]. Recent studies have shown that
EGFR signaling is also critically involved in TGFβ-induced ﬁbrotic gene
expression [68]. Signiﬁcantly higher levels of EGF have been detected
in the aqueous humour of nAMD patients compared with cataract pa-
tients [69]. A recent study has shown that cigarette smoke-induced
EMT in RPE cells is mediated through activation of the EGFR signaling
pathway [70]. The role of EGF-EGFR signaling pathway inmacular ﬁbro-
sis warrants further investigation.4.3.5. Fibroblast growth factor (FGF)
The FGFs are a family of cell signaling proteins consisting of at least
22 members and 4 receptors (FGFR1-4) [71]. The FGF-FGGR signaling
responses are involved in diverse biological processes, including prolif-
eration, migration, differentiation and apoptosis [71]. It has been re-
ported that FGF2 is involved in the development of ﬁbrosis in the
bonemarrow [72], lung [73], and retina [74]. Pharmacological inhibition
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ing CNV than inhibition of VEGF alone [74].
4.3.6. Sphingosine 1-phosphate (S1P)
S1P is implicated in the process of differentiation of ﬁbroblasts to
myoﬁbroblasts and the EMT [75]. A previous study has shown that
S1P is expressed at the lesion site in a mouse model of laser-induced
CNV/subretinal ﬁbrosis and intravitreal injection of anti-S1P monoclo-
nal antibodies reduces experimental CNV and retinal ﬁbrosis [76]. S1P
may play a role in macular ﬁbrosis in nAMD.
4.3.7. Alpha B-crystallin
αB-crystallin is amajor protein of the eye lens belonging to the small
heat-shock protein family. αB-crystallin is also found in various non-
ocular tissues and acts as amolecular chaperone by preventing aggrega-
tion of proteins, inhibiting apoptosis and inﬂammation, and maintain-
ing cytoskeletal architecture [77]. αB-crystallin is reported to be
involved in tissue ﬁbrosis including the retina [33].αB-crystallin can in-
duce EMT and enhance TGFβ-induced EMT in RPE cells through the
SMAD4 pathway [33].
4.3.8. Galectin
Galectins are S-type soluble lectins that bind speciﬁcally to β-
galactoside sugars with intra- and extracellular functions. Galectins
are known to play critical roles in cell-cell adhesion, cell-matrix interac-
tions, macrophage activation, angiogenesis, metastasis, and apoptosis.
Previous studies have shown that galectin-3 is involved in TGFβ-
mediated myoﬁbroblast activation [78] and increased plasma levels of
galectin-3 are associated with myocardial and vascular ﬁbrosis [79]
and systemic sclerosis [80]. Although macular ﬁbrosis in nAMD is a
vascularized ﬁbrotic lesion, we did not detect any difference in the
plasma levels of galectin-3 between nAMD patients with and without
macular ﬁbrosis and age-matched healthy controls (Yang et al., unpub-
lished observation). Galectin-1 was found to be upregulated in RPE in
the laser-CNV, and was reported to induce CNV-associated sub-retinal
ﬁbrosis through EMT [81]. The role of galectins in macular ﬁbrosis in
nAMD patients remains to be elucidated.
4.3.9. Decorin
Decorin is a proteoglycan that binds to collagen ﬁbrils in the ECM. It
can also interactwith various growth factors and their receptors, includ-
ing TGFβ and participate in angiogenesis and ﬁbrosis [82]. A recent
studyhas shown that increased decorin degradation is related toﬁbrotic
lung disorders [83]. Interestingly, we did not observe any difference in
the serum levels of decorin between nAMD patients and age-matched
controls. There was also no difference in serum levels of decorin be-
tween patients withmacular ﬁbrosis and thosewithout (Yang et al., un-
published observation). Whether the function of decorin is altered in
nAMD patients warrant further investigation.
4.3.10. Complement proteins
The complement system is an important arm of the innate immune
system, and dysregulated complement activation is known to be in-
volved in AMD [84,85]. Uncontrolled complement activation may con-
tribute to retinal pathology directly by damaging retinal cells using
the membrane attack complex (MAC, C5b-9) or indirectly by modulat-
ing inﬂammation with complement fragments e.g., C3a, C3b, and C5a
[84]. Previously, we reported that the plasma levels of C3a and C5a
were signiﬁcantly increased in nAMD patients, particularly those with
macular ﬁbrosis [86].
C5 polymorphisms have been reported in liver ﬁbrosis [87]. Deletion
of C5 or blocking C5a receptor suppresses ﬁbrosis in a mouse model of
late stage pancreatitis [88]. Furthermore, C3a can induce EMT in proxi-
mal tubular epithelial cells [89] and C3aR1 deletion inhibits interstitial
ﬁbrosis in mice [89]. We have found that C3a can induce MMT (Littleet al. ARVO 2018 Abstract). C3a and C5a may participate in macular ﬁ-
brosis in nAMD.
5. Therapeutic considerations
Macular ﬁbrosis in nAMD develops from existing neovascularmem-
brane. If the neovascularmembrane is eliminated at the very early stage
of nAMD, ﬁbrosis is unlikely to occur. Unfortunately, the majority of
CNV lesions cannot be completely eliminated with existing anti-VEGF
therapy. Furthermore, ~30% of nAMD patients do not respond to anti-
VEGF therapy, and the reasons behind this remain unclear. Future stud-
iesmay seek to understand this sub-set of patients, with aims to provide
a preventative treatment strategy for those susceptible to macular
ﬁbrosis.
When the neovascular lesion cannot be eliminated promptly, ap-
proaches should be taken to prevent ﬁbrosis in conjunction with VEGF
inhibition. This may include inhibiting ECM production at the initia-
tion/progression stages and promoting ECM degradation and uptake
at late stages of ﬁbrosis (e.g., the development of anti-ﬁbrotic
macrophages).
Myoﬁbroblasts are key for the development of macular ﬁbrosis.
Strategies to prevent the recruitment of myoﬁbroblast precursors or in-
hibit the activation or transdifferentiation of the precursors should ben-
eﬁt nAMD patients. The challenge is to identify key molecules
responsible for the recruitment or the activation/transdifferentiation
of myoﬁbroblast precursors. Among various growth factors discussed
here, only PDGF and CTGF have been tested in nAMD patients. Whilst
the therapeutic effect of CTGF inhibition remains to be evaluated, the in-
hibition of PDGF failed to show any additional beneﬁt in patients with
VEGF inhibition in phase 3 trials. This highlights the complexity of the
disease mechanism and the need for further understanding of the path-
ogenesis of the disease.
6. Outstanding questions and challenges
Recent clinical studies have uncovered the morphological features
and the dynamic changes of the ﬁbrotic lesion during different stages
of nAMD and following anti-VEGF therapy. However, the underlying
mechanism remains elusive. The pathogenesis of macular ﬁbrosis in
nAMD is different from a normal wound-healing ﬁbrotic scar as it arises
from a pre-existing neovascular membrane. The neovascular mem-
branes that originate from the retina (i.e., RAP) or invade the retina
from the choroid (i.e., classic CNV) or those with refractory intraretinal
cysts aremore likely to convert into ﬁbrous lesions, highlighting the im-
portance of retinal microenvironment in disease process. Fibroblasts do
not exist in the macula, nor in the abnormal new blood vessels. Future
researches should aim to understand the sources of myoﬁbroblast pre-
cursors, the molecular cues that attract them to macular neovascular
membranes and the pathways underlying their differentiation and
activation.
To address these important outstanding questions, we need to over-
comeanumber challenges. For example, laboratory examination of clin-
ically well-documented ﬁbrotic samples will be extremely helpful to
understand the cellular and molecular base of clinical presentations of
macularﬁbrosis. However, as surgery is no longer a treatment option, ﬁ-
brotic macula can only be obtained through donations, and matching
the clinical phenotype of the donated eye is often not possible.
Animal models are powerful tools to dissect disease pathways. Cur-
rently, rodents are most commonly used to study retinal ﬁbrosis. As ro-
dents have no macula, the models cannot truthfully replicate the
complexity of macular ﬁbrosis in patients. Nevertheless, they are valu-
able in dissecting speciﬁc pathways or testing drug candidates. For ex-
ample, the subretinal Matrigel implantation induced CNV and ﬁbrosis
in rats has been used to test the therapeutic effect of VEGF traps [90].
The model may also be useful in testing anti-ﬁbrosis drugs. Although
it can persist for 35 days [91], the subretinal ﬁbrosis following the
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human macular ﬁbrosis in nAMD (Fig. 3) [29]. The model, therefore,
has limited value in dissecting the molecular mechanism of macular ﬁ-
brosis. The injection of peritoneal macrophages into the subretinal
space immediately after the laser-induced CNV has resulted in a larger
size of subretinal ﬁbrosis [30]. The model has not been widely used
due to the technical challenges (e.g., macrophages need to be injected
precisely into the laser spot). Better animal models are urgently needed
to understand the pathogenesis of macular ﬁbrosis.
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